Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins.

Vaccine - 12 Nov 2014

Bissett Sara L, Mattiuzzo Giada, Draper Eve, Godi Anna, Wilkinson Dianna E, Minor Philip, Page Mark, Beddows Simon

Abstract excerpt

Human papillomavirus (HPV) vaccines confer protection against the oncogenic genotypes HPV16 and HPV18 through the generation of type-specific neutralizing antibodies raised against the constituent virus-like particles (VLP) based upon the major capsid proteins (L1) of these genotypes. The vaccines also confer a degree of cross-protection against some genetically related types from the Alpha-9 (HPV16-like: HPV31,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alphapapillomavirus
Share to Antibodies, Neutralizing

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antibodies, Viral

Share to Capsid Proteins

Share to Cross Protection

Share to Neutralization Tests

Share to Oncogene Proteins, Viral

Share to Papillomavirus Vaccines

Source

Open in PubMed Open full text

Identifiers

PMID: 25203446
DOI: 10.1016/j.vaccine.2014.07.116
PMCID: PMC4228199

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins.PMID 25203446Read ↗

HPV vaccine-induced cross-neutralising antibodies target complex epitopes on the major capsid proteinSemantic proximity Read ↗

A Chimeric 18L1-45RG1 Virus-Like Particle Vaccine Cross-Protects against Oncogenic Alpha-7 Human Papillomavirus TypesSemantic proximity Read ↗

Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like ParticlesSemantic proximity Read ↗

L2 epitope presenting virus-like particles as broad- spectrum vaccine candidates targeting genus beta human papillomavirusesSemantic proximity Read ↗

Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.Semantic proximity Read ↗

Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody.Semantic proximity Read ↗

Immunological analyses of human papillomavirus capsids.Semantic proximity Read ↗

Rational design of a cross-type HPV vaccine through immunodominance shift guided by a cross-neutralizing antibodySemantic proximity Read ↗

Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV)Semantic proximity Read ↗

Concatenated Multitype L2 Fusion Proteins as Candidate Prophylactic Pan-Human Papillomavirus VaccinesSemantic proximity Read ↗

Serologic response to human papillomavirus genotypes following vaccination: findings from the HITCH cohort study.Semantic proximity Read ↗

Progress in L2-Based Prophylactic Vaccine Development for Protection against Diverse Human Papillomavirus Genotypes and Associated DiseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.